Written Question · S4W-05553 · Session 4
Whether the drug, Xiapex, for the treatment of Dupuytren’s contracture is available to the NHS.
The question
To ask the Scottish Executive whether the drug, Xiapex, for the treatment of Dupuytren’s contracture is available to the NHS.
The answer
The Scottish Medicines Consortium (SMC) appraised collagenase clostridium histolyticum injection (Xiapex®) for the treatment of Dupuytren’s contracture in adult patients with a palpable cord and published “not recommended” advice in August 2011.
NHS boards and clinicians are expected to take full account of advice from the Scottish Medicines Consortium. Where the SMC does not accept a new medicine, NHS boards are not expected to make it routinely available. However, NHS boards have arrangements in place for the clinical consideration of SMC “not recommended” medicines for individual patients in certain circumstances (individual patient treatment requests).
NHS boards and clinicians are expected to take full account of advice from the Scottish Medicines Consortium. Where the SMC does not accept a new medicine, NHS boards are not expected to make it routinely available. However, NHS boards have arrangements in place for the clinical consideration of SMC “not recommended” medicines for individual patients in certain circumstances (individual patient treatment requests).
In the Official Report
No contribution in the Official Report cites S4W-05553 by reference.